From the Watchtower · Page 4
Oncology intelligence, in the open.
Briefings 73–75 of 75, newest first.
AstraZeneca's NCT06764875 pits a rilvegostomig–Enhertu regimen against the pembrolizumab comparator in first-line HER2+ gastric cancer
A three-arm, 840-patient Phase 3, recruiting now, primary completion estimated April 2029, tests AstraZeneca's largely owned rilvegostomig-plus-Enhertu combination against trastuzumab + chemotherapy + pembrolizumab.
Elicio's KRAS vaccine missed its Phase 2 primary endpoint. It's staking a Phase 3 on the subgroup that worked.
ELI-002 7P failed disease-free survival in the AMPLIFY-7P intent-to-treat population, and Elicio is pressing into a larger, R0-enriched Phase 3 on a post-hoc result and a runway that ends in Q4 2026.
Spectrum Exits the Poziotinib Exon 20 Program: Four Trials Halted, Stated Reasons Explicitly Exclude Safety
Four terminated or suspended studies, zero Phase 3 enrollees, active FDA redesign talks: stated reasons across all Spectrum-sponsored poziotinib terminations explicitly exclude safety, the regulatory and strategic picture is the story.